| 1 |
34748184 | Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease. | 2022 Jan |
1 |
| 2 |
32238734 | The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function. | 2021 Jan 8 |
2 |
| 3 |
32841939 | Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease. | 2021 |
1 |
| 4 |
33466174 | Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report. | 2021 Jan 15 |
1 |
| 5 |
33644726 | Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. | 2021 Apr |
1 |
| 6 |
33797208 | Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease. | 2021 May |
1 |
| 7 |
34386595 | A cost-effectiveness analysis of lusutrombopag for thrombocytopenia in patients with chronic liver disease in Japan. | 2021 Aug |
2 |
| 8 |
32205226 | Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. | 2020 Oct |
1 |
| 9 |
32510789 | Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching. | 2020 Sep |
1 |
| 10 |
32550846 | Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS. | 2020 |
1 |
| 11 |
32620282 | Thrombocytopenia in Chronic Liver Disease: New Management Strategies. | 2020 Aug |
1 |
| 12 |
32666123 | Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters. | 2020 Dec |
2 |
| 13 |
32813292 | Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. | 2020 Oct |
1 |
| 14 |
33317473 | Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study. | 2020 Dec 14 |
1 |
| 15 |
29274361 | Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl. | 2018 Mar |
6 |